 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...6768697071727374757677...123124» |
- Phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced clear cell renal cell carcinoma (ccRCC). (In-Person & On Demand | Level 1, West Hall) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_795;
P1b/2
Secondary end points during the efficacy phase are duration of response, progression-free survival (RECIST v1.1 by BICR), clinical benefit rate, and overall survival. Both substudies are recruiting patients in Australia, Canada, France, Israel, South Korea, Spain, New Zealand, the United Kingdom, and the United States.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer. (In-Person & On Demand | Level 1, West Hall - M6) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_793;
P3
Cabozantinib + nivolumab and lenvatinib + pembrolizumab combinations are being added into the next amendment...The study hypothesis is that CN will result in improvement in OS outcomes in advanced synchronous RCC post-initial systemic immune checkpoint based combination therapy. With a sample size of 302 eligible, randomized participants (151 per arm) and a one-sided alpha = 0.025, the study has 85% power to detect a 47% improvement in median survival (HR = 0.68; 1/0.68 = 1.47)
- Keytruda (pembrolizumab) / Merck (MSD), Welireg (belzutifan) / Merck (MSD), quavonlimab (MK-1308) / Merck (MSD)
Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC). (In-Person & On Demand | Level 1, West Hall - M3) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_790;
P3
Secondary end points are objective response rate and duration of response per RECIST v1.1 by BICR, patient-reported outcomes, and safety. The study is recruiting patients at sites across, Asia, Australia, Europe, North America, and South America.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Network meta-analysis (NMA) of first-line advanced renal cell carcinoma (1L aRCC) treatments: Development of a decision algorithm for fractional polynomial (FP) model selection. (In-Person & On Demand | Level 1, West Hall - J10) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_759;
In our study, FP models generally performed imperfectly against some of the trial data. This likely reflects heterogeneity between trial populations, differing MoAs and subsequent treatments and highlights further research is needed on the integration of adjustment for heterogeneity in the fitting of FP models.
- Keytruda (pembrolizumab) / Merck (MSD)
Association between biomarkers and clinical outcomes of lenvatinib + pembrolizumab in advanced renal cell carcinoma (RCC): Results from Study 111/KEYNOTE-146. (In-Person & On Demand | Level 1, West Hall - H8) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_743;
P1b/2
There were no statistically significant associations between gene signatures and clinical outcomes. Clinical benefit was observed regardless of VHL, PBRM1, BAP1, or SETD2 mutation status.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Assessing physician prescribing behaviors in first-line (1L) advanced renal cell carcinoma (aRCC): A case-based study. (In-Person & On Demand | Level 1, West Hall) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_724;
Meeting primary endpoints is a strong influencer in providers’ decision-making. Given the nonsignificant difference in preference for PA over NC, further research is needed to assess factors influencing providers’ decisions.
- Keytruda (pembrolizumab) / Merck (MSD), Sutent (sunitinib) / Pfizer
Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial. (In-Person & On Demand | Level 1, West Hall) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_707;
P3
Efficacy results for patients in the East Asian subset of the CLEAR trial were consistent with the results of the overall population. The safety profile of LEN + PEMBRO in the East Asian subset was also generally consistent with that of the overall population.
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Network meta-analysis (NMA) of second-line (2L) treatment options in metastatic renal cell carcinoma. (In-Person & On Demand | Level 1, West Hall - F8) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_706;
This NMA revealed that lenvatinib+everolimus and cabozantinib are most likely to produce the highest PFS benefit in 2L in mRCC. Future studies are needed to evaluate 1L and 2L sequencing options to further inform clinical practice.
- Avastin (bevacizumab) / Roche, Sutent (sunitinib) / Pfizer, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
A VA Federal Supply Schedule (VAFSS)–based cost-effectiveness analysis of immunotherapy-tyrosine kinase inhibitor (IO-TKI) regimens and sunitinib in the treatment of metastatic renal cell carcinoma (mRCC). (In-Person & On Demand | Level 1, West Hall - E2) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_681;
The 7 treatment drug strategies considered in this model included: (1) atezolizumab + bevacizumab (AB), (2) avelumab + axitinib (AA), (3) pembrolizumab + axitinib (PA), (4) nibolumab + ipilimumab(NI), (5) nibolumab + cabozantinib (NC), (6) lenvatinib + pembrolizumab (LP), and (7) sunitinib (S)... Our analyses suggest that based on direct cost acquisition using VA FSS, PA or AA were cost-effective strategies for mRCC with WTP of $20,000 to $200,000 per QALY.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC). (In-Person & On Demand | Level 1, West Hall) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_679;
Presence of lung metastases, CN and better IMDC risk group are associated with a higher probability of response to 1L immunotherapy combination regimens. Further work to identify reliable predictors of response to guide treatment selection and patient counselling is warranted.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC). (In-Person & On Demand | Level 1, West Hall - D11) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_677;
In addition, these findings mirror the efficacy of combination therapies established in clinical trials against VEGF-TT monotherapy. IMDC criteria continue to risk stratify patients in these novel combination therapies.
- Keytruda (pembrolizumab) / Merck (MSD)
KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab + lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE). (In-Person & On Demand | Level 1, West Hall - R7) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_235;
P1/2
Secondary end points include time to PSA progression; ORR and radiographic progression-free survival per Prostate Cancer Working Group 3 (PCWG3)–modified RECIST v1.1 by BICR; duration of response and disease control rate per RECIST v1.1 and PCWG3-modified RECIST v1.1 by BICR; and overall survival. These cohorts of KEYNOTE-365 are enrolling in Australia, Germany, New Zealand, Spain, and the United States.
- Keytruda (pembrolizumab) / Merck (MSD)
First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study. (Available On Demand) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_164;
P3
The benefit/risk ratio for pembro + lenva was not considered positive vs pembro + placebo in platinum-ineligible pts with advanced UC. Antitumor activity of pembro + placebo was similar to what has been reported in previous studies, and pembro monotherapy remains standard of care as first-line therapy in platinum-ineligible pts with advanced UC.
- || lenvatinib / Generic mfg.
Clinical, Journal: Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview. (Pubmed Central) - Jan 5, 2022
Efficacy of lenvatinib appears limited, although pure versus mixed ATC disclose differences in disease aggressiveness and treatment response. Long-surviving ATC patients might benefit from biopsy of persistent disease, searching for histological transition or molecular target.
- | Cilcane (cilengitide) / Iceni Pharma
Journal: A positive feedback loop between Periostin and TGFβ1 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2α activation. (Pubmed Central) - Jan 5, 2022
The POSTN/TGFβ1 positive feedback pathway regulates the expression of stemness factors and the malignant progression of HCC cells by regulating the transcriptional activation of AP-2α. This pathway may serve as a new target for targeted gene therapy in HCC.
- | lenvatinib / Generic mfg.
#KnightTherapeuticsInc Announces Approval of #Lenvima in Colombia $GUD https://t.co/rJmhbAclrT (Twitter) - Jan 5, 2022
- || lenvatinib / Generic mfg.
Clinical, Journal: Correlation of Performance Status and Neutrophil-Lymphocyte Ratio With Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated With Lenvatinib. (Pubmed Central) - Jan 4, 2022
P3
Lower ECOG PS and NLR may provide prognostic value for improved efficacy in patients with RR-DTC. .
- || Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen
Review, Journal: Conversion Surgery for Hepatocellular Carcinoma Following Molecular Therapy. (Pubmed Central) - Jan 4, 2022
In conclusion, conversion surgery following molecular therapy is a promising treatment strategy for prolonging long-term outcomes. We should discuss promising drugs and the timing for conversion surgery.
- | lenvatinib / Generic mfg.
Retrospective data, Journal, Monotherapy: A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China. (Pubmed Central) - Jan 4, 2022
ICC patients did not reach the mOS and their mPFS was 8.63 months. The present findings support the efficacy and security of Lenvatinib in the real-world therapy of Chinese patients with unresectable liver cancer.
- || Keytruda (pembrolizumab) / Merck (MSD)
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Uterine serous carcinoma. (Pubmed Central) - Jan 1, 2022
At present, ongoing studies are testing novel combinations of various targeted and immunotherapeutic agents in newly diagnosed and advanced/recurrent endometrial cancer - an important strategy for serous endometrial cancer, whereby tumors are usually p53+ and pMMR, making response to PD-1 inhibitor monotherapy unlikely. Here, the rare tumor working group (including members from the European Society of Gynecologic Oncology (ESGO), Gynecologic Cancer Intergroup (GCIG), and Japanese Gynecologic Oncology Group (JGOG)), performed a narrative review reporting on the current landscape of serous endometrial cancer and focusing on standard and emerging therapeutic options for patients affected by this difficult disease.
- || Keytruda (pembrolizumab) / Merck (MSD)
Clinical, Journal: Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. (Pubmed Central) - Jan 1, 2022
The combination produced responses in endometrial carcinosarcomas. Larger studies are required to validate these findings.
- Opdivo (nivolumab) / Ono Pharma, BMS
Safety and Efficacy of Lenvatinib Plus Nivolumab in Unresectable Hepatocellular Carcinoma: A Retrospective Study in China (ePoster/eVideo) - Dec 31, 2021 - Abstract #IHPBA2022IHPBA_1013;
- lenvatinib / Generic mfg.
Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study (ePoster/eVideo) - Dec 31, 2021 - Abstract #IHPBA2022IHPBA_1008;
- || everolimus / Generic mfg., lenvatinib / Generic mfg.
Interesting data! Will be fascinating to see how Lenvatinib everolimus does in this subgroup! (Twitter) - Dec 30, 2021
- | lenvatinib / Generic mfg.
Journal: Lenvatinib targets PDGFR-β pericytes and inhibits synergy with thyroid carcinoma cells: novel translational insights. (Pubmed Central) - Dec 30, 2021
This is the first thyroid-specific model of lenvatinib therapeutic efficacy against pericyte viability, which disadvantages BRAF WT/V600E-PTC growth. Assessing pericyte abundance in patients with PTC could be essential to selection rationales for appropriate targeted therapy with lenvatinib.
- | lenvatinib / Generic mfg.
Journal: Lenvatinib exposure induces hepatotoxicity in zebrafish via inhibiting Wnt signaling. (Pubmed Central) - Dec 29, 2021
Therefore, these results suggested that lenvatinib might induce zebrafish hepatotoxicity by down-regulating Wnt signaling related genes and inducing oxidative stress. This study provides a reference for the potential hepatotoxicity of lenvatinib during embryonic development and raises health concern about the potential harm of exposure to lenvatinib for foetuses.
- || lenvatinib / Generic mfg.
Clinical, Journal: A case of lenvatinib therapy-induced unilateral interstitial pneumonia and cavity formation in advanced liver cancer (Pubmed Central) - Dec 29, 2021
This study provides a reference for the potential hepatotoxicity of lenvatinib during embryonic development and raises health concern about the potential harm of exposure to lenvatinib for foetuses. No abstract available
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial, Metastases: Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer (clinicaltrials.gov) - Dec 28, 2021
P1, N=19, Recruiting, Sponsor: Ruijin Hospital
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Metastases: Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) (clinicaltrials.gov) - Dec 28, 2021
P3, N=750, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
No abstract available Trial completion date: May 2022 --> Dec 2023
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Metastases: Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma (clinicaltrials.gov) - Dec 28, 2021
P1, N=20, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: May 2022 --> Dec 2023 Active, not recruiting --> Completed
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: LenPac: Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment (clinicaltrials.gov) - Dec 28, 2021
P2, N=55, Not yet recruiting, Sponsor: National Health Research Institutes, Taiwan
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma (clinicaltrials.gov) - Dec 28, 2021
P2, N=40, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Combination therapy: Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients (clinicaltrials.gov) - Dec 28, 2021
P2, N=50, Not yet recruiting, Sponsor: The Methodist Hospital Research Institute
- Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab+Lenvatinib: the promising combination treatment for advanced solid tumors (Room B) - Dec 27, 2021 - Abstract #AACRKCA2021AACR_KCA_60;
Not yet recruiting --> Recruiting Sponsored by MSD
- || Avastin (bevacizumab) / Roche
Clinical, Review, Journal: Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue "Diagnosis and Management of Endometrial Cancer". (Pubmed Central) - Dec 27, 2021
In a recent study, the combination of lenvatinib + pembrolizumab produced a 24-week response rate of 38% in patients with highly pretreated EC, ranging from 64% in patients with MSI-H/MMR-d to 36% in those with microsatellite stable/MMR-proficient tumors. Four trials are currently investigating the addition of immune checkpoint inhibitors to PTX + CBDCA in primary advanced or recurrent EC, and two trials are comparing pembrolizumab + lenvatinib versus either CBDCA + PTX as a first-line treatment of advanced or recurrent EC or versus single-agent chemotherapy in advanced, recurrent or metastatic EC after one prior platinum-based chemotherapy.
- || Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
Review, Journal: Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib. (Pubmed Central) - Dec 27, 2021
Anti-vascular endothelial growth factor (anti-VEGF) antibodies can be used in first-line (bevacizumab) or second-line (ramucirumab) combination therapy...We will discuss the place of lenvatinib in first line (especially if there is a contra-indication to IO) but also after failure of atezolizumab and bevacizumab. New opportunities for lenvatinib will also be presented, including the use at an earlier stage of the disease and combination with IOs.
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: Combination of psoas muscle mass index and neutrophil/lymphocyte ratio as a prognostic predictor for patients undergoing nonsurgical hepatocellular carcinoma therapy. (Pubmed Central) - Dec 27, 2021
In addition, the prognostic formula composed of PMI, NLR, and up-to-seven criteria developed in the present study may be useful. PMI and NLR are considered to be independent prognostic factors for HCC.
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: LEAP-003 China Extension: Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study (clinicaltrials.gov) - Dec 27, 2021
P3, N=130, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
PMI and NLR are considered to be independent prognostic factors for HCC. Recruiting --> Active, not recruiting
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Lenvatinib and Pembrolizumab in People with Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers (clinicaltrials.gov) - Dec 23, 2021
P2, N=64, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
New P2 trial, Combination therapy, Metastases: ACCRU-GI-2008: Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer (clinicaltrials.gov) - Dec 23, 2021
P2, N=122, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
- || lenvatinib / Generic mfg.
Clinical, P4 data, PK/PD data, Journal, Real-world evidence: Pharmacodynamic Analysis of Hypertension Caused by Lenvatinib Using Real-World Post-marketing Surveillance Data. (Pubmed Central) - Dec 23, 2021
Based on virtual simulations, the combination of antihypertensive drug and dose adjustment of lenvatinib showed a reduction in the probability of Grade ≥ 3 hypertension. The present model provides useful guidance in managing hypertension during treatment with lenvatinib in the real-world setting.
- || Clinical, Review, Journal: Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. (Pubmed Central) - Dec 23, 2021
Between 2017 and 2020, the United States Food and Drug Administration (FDA) approved a variety of drugs for the treatment of HCC, including multikinase inhibitors (regorafenib, lenvatinib, cabozantinib, and ramucirumab), immune checkpoint inhibitors (nivolumab and pembrolizumab), and bevacizumab combined with atezolizumab...In addition, we introduce the development of HCC drugs in China. Finally, we discuss potential problems in HCC drug therapy and possible future solutions and indicate future directions for the development of drugs for HCC treatment.
- Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta-analysis of safety (Green Area, Room 5) - Dec 22, 2021 - Abstract #EAU2022EAU_1468;
Everolimus, with the best ranking of safety, was more likely to be selected for combination therapies. This study will guide treatment choice and optimize the future trial design for advanced or metastatic RCC.
- || lenvatinib / Generic mfg.
Clinical, Journal: Colonic metastasis of hepatocellular carcinoma with repeated retroperitoneal bleeding: a case report. (Pubmed Central) - Dec 21, 2021
This study will guide treatment choice and optimize the future trial design for advanced or metastatic RCC. Resection of metastasis of HCC might contribute to prolonged survival in cases, where radical resection is possible.
- ||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Keytruda (pembrolizumab) / Merck (MSD)
Clinical, Journal, Adverse events: Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case report. (Pubmed Central) - Dec 21, 2021
We present a case of laparoscopic hepatectomy after receiving lenvatinib plus pembrolizumab and developed hypothyroidism and hypopituitarism after surgery. Regarding surgery after ICI therapy, it is important to recognize that irAEs might occur in the postoperative period.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal: Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pre-treated recurrent and metastatic head and neck cancer. (Pubmed Central) - Dec 21, 2021
Our study provided up-to-date evidence that pembrolizumab/lenvatinib combination therapy achieved objective responses in both heavily pretreated and anti-PD-1 refractory R/M HNSCC patients. This study supported the use of pembrolizumab/lenvatinib combination therapy in R/M HNSCC patients without standard of care.
- || Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
Review, Journal: Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer-Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension. (Pubmed Central) - Dec 21, 2021
Sorafenib, lenvatinib and cabozantinib are multikinase inhibitors (MKIs) approved for the treatment of RAI-refractory DTC...In short, treatment-emergent hypertension (TE-HTN) occurs with all three drugs, but is usually well manageable and leads only to a few dose modifications or even discontinuations. This is emphasized by the fact that lenvatinib is widely considered the first-line drug of choice, despite its higher rate of TE-HTN.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT (clinicaltrials.gov) - Dec 20, 2021
P2, N=66, Not yet recruiting, Sponsor: Peking University
- || lenvatinib / Generic mfg.
Clinical, Journal: Postoperative recurrence with right cervical lymph node metastasis in hepatocellular carcinoma: a case report. (Pubmed Central) - Dec 20, 2021
This is emphasized by the fact that lenvatinib is widely considered the first-line drug of choice, despite its higher rate of TE-HTN. After resection of HCC in the right upper lobe, there is the possibility of metastatic lymph node recurrence in unusual sites, including the cervical region, and lenvatinib may be effective in those recurrences.